Oral Cancer Drugs Deserve Parity
There have been some legislative efforts to bring parity to oral cancer drugs so that insurance companies treat them the same way as injectable cancer drugs.
The American Cancer Society takes a cautious approach to oral parity. Stephen Finan, senior director of policy for the American Cancer Society Cancer Action Network, said in an e-mail that the group is monitoring the issue "to better understand how health plans are handling coverage for both oral and injectable treatments -- specifically to make sure that affordability isn't challenged through increased premiums, stricter utilization management tools or exclusion of anti-cancer medications from formularies to contain costs."
Margaret Dick Tocknell is a reporter/editor with HealthLeaders Media.
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- New G-Codes to Pay Doctors for Broad Array of Non-Face-to-Face Care
- FDA hopes hospitals will switch to newly regulated pharmacies
- States Rejecting Medicaid Expansion Forgo Billions in Federal Funds
- Why You Should Involve Patients in Nursing Handoffs
- Douglas Hawthorne—A Chance to Do Something Big
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- Substance Abuse Resurfaces Among Anesthesiologists in Training
- The 5 Biggest Healthcare Finance Trouble Spots
- 'Country Doctor of the Year' Embraces Challenges of Rural Medicine